QuantiLight, a startup developing an In-vitro Diagnostic platform for at-home therapeutic drug monitoring, has secured $1.3M in pre-seed funding. The round was led by Health + Life Science Alliance.
The company's platform leverages bioluminescent sensor technology from the Max-Planck-Institute for Medical Research to provide chronic patients and healthcare professionals with actionable blood test results in just 15 minutes. This approach aims to empower patients through a secure app, reducing hospital visits and environmental impact while saving costs for the healthcare system.


















